Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAII)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended March 31, 2025
Business Overview: NAII operates in two primary segments: private-label contract manufacturing of nutritional supplements and patent/trademark licensing (primarily beta-alanine ingredients under the CarnoSyn® and TriBsyn™ brands). The company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Mar 31, 2025 | 9 Months Ended Mar 31, 2025 |
|---|---|---|
| Net Sales | $28,766 | $95,994 |
| Gross Profit | $1,826 | $5,754 |
| Gross Margin | 6.3% | 6.0% |
| Loss from Operations | $(2,100) | $(6,716) |
| Net Loss | $(2,186) | $(6,359) |
| Net Loss Per Share (Basic/Diluted) | $(0.37) | $(1.07) |
| Cash and Cash Equivalents | $10,611 | $10,611 (as of Mar 31, 2025) |
| Net Cash Provided by Operating Activities | N/A | $2,587 |
| Total Debt (Line of Credit + Term Loan) | $11,003 | $11,003 (as of Mar 31, 2025) |
Note: Total Debt includes $2.0 million on the line of credit and $9.0 million on the term loan.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% year-over-year for the nine months ended March 31, 2025, driven by a 16% increase in private-label contract manufacturing sales. This was offset by a 9% decline in patent and trademark licensing revenue.
- Margin Compression: Gross profit margin decreased to 6.0% for the nine-month period (down from 6.5% in the prior year). This was attributed to lower-margin contract manufacturing volume and decreased high-margin licensing sales.
- Increased Losses: Net loss increased 19% to $6.4 million for the nine-month period. Operating losses widened due to factory underutilization, increased SG&A expenses (legal and compensation), and higher interest costs.
- Foreign Exchange Impact: Foreign exchange losses increased significantly to $0.6 million for the nine months ended March 31, 2025, compared to $0.5 million in the prior year, impacting other income/expense.
Guidance, Outlook, and Risks
- Outlook: Management anticipates an overall net loss for fiscal year 2025 despite a forecasted sales increase in the fourth quarter. The company expects revenue concentration from its largest customer to decrease compared to fiscal 2024.
- Credit Facility Covenant Breach: As of March 31, 2025, the company was not in compliance with financial covenants (net income and fixed charge coverage ratio) under its Wells Fargo credit facility. Management anticipates non-compliance will continue into the fourth quarter.
- Debt Restructuring: A tentative agreement exists with Wells Fargo to waive past and current violations. A Fifth Amendment was executed on May 14, 2025, extending the credit facility maturity to June 23, 2025, to allow time for finalizing a new amended agreement. There is no assurance a new facility will be secured.
- Key Risks:
- Customer Concentration: One customer accounted for 35% of net sales in the first nine months of fiscal 2025.
- Supply Chain & Tariffs: Reliance on limited suppliers for beta-alanine and potential adverse effects from new U.S. trade tariffs on imported ingredients.
- Geopolitical Instability: Conflicts in Ukraine and the Middle East may impact raw material sourcing (specifically from Israel) and global shipping costs.
- IRS Dispute: The IRS has denied a portion of the Employee Retention Tax Credit (ERTC) claim for Q3 2021; the company is contesting this denial.
Investor Verification Checklist
- Credit Facility Status: Verify the final terms of the amended credit agreement with Wells Fargo and the company's ability to secure long-term financing given the covenant breaches.
- Customer Concentration: Monitor the stability of the top customer (35% of sales) and the success of diversification efforts.
- Licensing Revenue Trend: Assess the trajectory of the declining patent and trademark licensing segment and the market adoption of the new TriBsyn™ product.
- IRS ERTC Outcome: Track the resolution of the IRS dispute regarding the $3.5 million ERTC claim, specifically the denied Q3 2021 portion.
- Margin Recovery: Evaluate whether increased sales volume will sufficiently offset fixed costs to improve gross margins and achieve profitability in future quarters.